Jeuveau shows fast onset and long duration in neurotoxin study

NEWPORT BEACH, Calif. - A landmark independent study published in JAMA Dermatology has directly compared four FDA-approved botulinum toxin products for treating glabellar lines, finding that Jeuveau (prabotulinumtoxinA-xvfs) demonstrated fast onset, strong peak effect, and long duration.

The double-blind, randomized study conducted at the University of Pennsylvania involved 143 female participants aged 30 to 65 who received FDA-approved doses of either Jeuveau, Botox (onabotulinumtoxinA), Dysport (abobotulinumtoxinA), or Xeomin (incobotulinumtoxinA). Researchers used 3-dimensional photogrammetry to objectively measure efficacy at days 3, 30, 90, and 180.

According to the published findings, Jeuveau and Dysport showed significantly faster visible effects at Day 3 compared to Botox and Xeomin. At Day 30, Jeuveau achieved the highest peak effect with a median strain reduction of 93%. The study also found that Jeuveau maintained significant duration at Day 180 compared with baseline and was significantly more effective than Botox at this time point.

"The results add to what we observed in our prior head-to-head study with Botox, while also offering valuable comparative insights across the broader landscape of aesthetic neurotoxins," said Dr. Rui Avelar, Chief Medical Officer and Head of R&D of Evolus (NASDAQ:EOLS).

Since its launch, Jeuveau has become the fastest-growing neurotoxin in the U.S. for four consecutive years and currently holds over 14% U.S. market share, according to the company’s press release statement. With a market capitalization of $577.7 million, Evolus currently trades near its 52-week low, while analysts maintain a strong buy consensus with significantly higher price targets. Investors can access detailed analysis and additional insights through InvestingPro’s comprehensive research report, which is part of their coverage of over 1,400 U.S. stocks.

The study was funded by Evolus through an investigator-initiated research grant. The company stated it was not involved in the design, protocol development, or conduct of the research, which was carried out independently by the investigators. Investors looking for additional catalysts should note that Evolus is scheduled to report its next earnings on August 5, 2025. InvestingPro subscribers can access 6 additional key insights about Evolus, including detailed financial health scores and valuation metrics.

In other recent news, Evolus reported its first-quarter 2025 earnings, which revealed a larger-than-expected loss with an EPS of -$0.30, missing analysts’ forecast of -$0.09. Despite the earnings miss, Evolus experienced a revenue increase to $68.5 million, marking a 15.5% rise year-over-year, although still below the anticipated $72.51 million. The company’s recent achievements include the launch of a second product line and record revenues, which have set the stage for future profitability. Evolus announced the resignation of its Chief Financial Officer, Sandra Beaver, who will transition to a new role at a private mental health and wellness technology firm. This change in leadership comes as Evolus continues to focus on expanding its portfolio of aesthetic treatments. In a clinical study, Evolus’s Evolysse™ Form and Evolysse™ Smooth products showed statistical superiority to a leading competitor, Restylane®-L, in treating facial wrinkles. Analysts at Stifel and Mizuho have maintained their positive outlooks, with both firms keeping their price targets at $25.00, reflecting confidence in Evolus’s strategic direction. Evolus’s leadership remains committed to achieving non-GAAP profitability and meeting projected sales targets by 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.